Baiya International Group reported a reduced net loss of $2.4 million for the first half of fiscal 2026, down from $4.8 million a year earlier, driven by $0.8 million in revenue from its new intelligent matching and SaaS platform. Operating expenses fell 31.6% to $3.5 million, reflecting cost-cutting efforts and the sale of a subsidiary. The company plans to further develop its SaaS-enabled human capital platform to boost growth and shareholder value. Cash increased to $1.2 million, supporting ongoing operations amid the transition to new business lines.
Baiya International Group Inc.'s first half of fiscal 2026 financial results provide context as of Sep 30, 2026 03:02 WIB. For readers following the Technology sector, here is Pluang's market snapshot: out of 150 priced US tech stocks, 63 rose and 87 fell. Notable movers include WIX at USD 69.60 with a 1-day change of -5.68%, DUOL at USD 141.48 with +5.35%, and AMAT at USD 512.00 with +5.19%. The most notable figure is the 87 stocks that declined today.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
